Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Next Previous
Search
Trial Profile

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemvidutide (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms IMPACT trial
  • Sponsors Altimmune

    • Most Recent Events

    • 27 Feb 2025 According to an Altimmune media release, company is on track for top-line data readout in Q2 2025.
    • 15 Oct 2024 According to an Altimmune media release, topline data expected in the second quarter of 2025.
    • 30 Sep 2024 According to an Altimmune media release, company announced completion of patient enrollment in IMPACT trial with top-line efficacy data expected in the second quarter of 2025. Company have received FDA confirmation of the End-of-Phase 2 meeting for our obesity program, which is scheduled for early November 2024. Dr. Mazen Noureddin, M.D., MHSc is the Principal Investigator on the IMPACT trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top